Prezista (Darunavir, TMC114)

The Basics | News | Research

Show Archived (Historical) Articles

Brand Name:	Prezista
Generic Name:	darunavir, TMC114
Adult Single Dose:	Two 300 mg tablets twice daily taken with ritonavir 100 mg twice daily.
Food & Liquid Restrictions:	Take with food.
Drug Class:	PI

The Basics

An Overview of Prezista (Darunavir, TMC114) (Regularly Updated)
From AIDSinfo
Patient Information About Prezista (Darunavir, TMC114) (PDF) (January 2010)
From Tibotec Therapeutics
Darunavir (Prezista) (July 31, 2009)
To read PDF, click here.
From AIDS InfoNet
Prezista (March/April 2009)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Prezista (Darunavir, TMC-114) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
An Interview With Cal Cohen, M.D., a Lead Investigator of the Darunavir (TMC114, Prezista) POWER Trials (June 28, 2006)
Dr. Cohen discusses TMC114's uses, adverse effects and other considerations.
Prezista Approval (June 23, 2006)
From U.S. Food and Drug Administration

News

U.S. Food and Drug Administration Approves Labeling Update for Prezista to Include 96-Week Data in HIV-1 Infected Adult Patients (January 28, 2010)
From Tibotec Therapeutics
Prezista Now Available for Pediatric Patients Six Years of Age and Older as Part of HIV Combination Therapy (February 11, 2009)
From Tibotec Therapeutics
New 75 mg Prezista Tablet and Corresponding Pediatric Dosing Information Approved (December 18, 2008)
From U.S. Food and Drug Administration
HIV/AIDS Update - Important information about Prezista (darunavir) (October 22, 2008)
From U.S. Food and Drug Administration
Updates to Prezista (Darunavir) Tablets Labeling (March 11, 2008)
From U.S. Food and Drug Administration
"Dear Healthcare Professional" Letter: New Prescribing Information for Prezista (Darunavir) (March 2008)
Labeling has been updated to include warnings regarding hepatotoxicity.
From Tibotec Therapeutics
New 600-mg Tablet Strength for Prezista (Darunavir) (February 26, 2008)
From U.S. Food and Drug Administration
A Drug Pricing Victory: Tibotec Prices Prezista at Far Below Cost of Reyataz, Fuzeon (June 30, 2006)

Research

Once-Daily Darunavir in Treatment-Experienced Patients (March 8, 2010)
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Once-Daily Darunavir Effective and Less Toxic Than Twice-Daily in Experienced Patients Without Prior Darunavir Resistance: ODIN (February 18, 2010)
From aidsmap.com
Prezista Monotherapy May Prove Effective (February 1, 2010)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
Boosted Darunavir Monotherapy Works Well in Two Studies (July 23, 2009)
Ritonavir-boosted darunavir alone maintains HIV suppression in most patients who achieved an undetectable viral load on combination antiretroviral therapy, according to two studies.
From aidsmap.com
Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
GRACE Under Pressure (December 2006)
To read PDF, click here.
In TAGline, from Treatment Action Group
48-Week TMC114 + Ritonavir Data Set New Bar for Efficacy in Triple-Class-Experienced Patients (August 15, 2006)
In XVI International AIDS Conference

My Health Tracker

Join Us on Facebook

Widgets and RSS Feeds

U.S. ASO Finder

CROI 2010 Wrap-Up: The HIV Drug Development Pipeline

CROI 2010 Wrap-Up: The Evolution of Antiretroviral Therapy

HIV Vaccine Trial Lessons: What Researchers Learned From the STEP Study's Failure and the RV144 ("Thai") Study's Success

This Positive Life: An Interview With Gary

Why There's Such an HIV/AIDS Disparity Among U.S. Blacks and Hispanics -- and What to Do About It

More >>

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.